News

Research suggests that tildrakizumab may be useful in real-life settings against moderate-to-severe plaque psoriasis.

In this regularly scheduled September 2022 episode of Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide their own perspective on DIY looping based on the results of a recent study published in the New England Journal of Medicine and also break down a new set of consensus recommendations for the use of automated insulin delivery (AID) systems in clinical practice published in Endocrine Reviews, which Isaacs helped compose as a member of the writing committee.

PP-IRF through year 2 was independently associated with worse long-term visual acuity and scar development.

Patients with nAMD, DME, BRVO-ME, and CRVO-ME showed limited visual acuity outcomes in clinical practice.

NAFLD resulted in a number of other negative outcomes, including sleep disturbance, cardiovascular disease, significant hepatic fibrosis, and advanced hepatic fibrosis.

Conflicting evidence on the risks associated with intubation in patients with COVID-19 initiated a debate in the medical community regarding the benefit of utilizing high-flow oxygen.

A discussion was held regarding research on the use of antivirals on younger influenza patients.

The association between cumulative BMI and risk of NAFLD was more pronounced in women and younger participants.

Research has highlighted new information for the identification of risk factors for dementia.

Dr. Craig Granowitz of Lexicon Pharmaceuticals details the success of the LX9211 clinical trial for painful diabetic neuropathy and the unique study design.

Research finds potential benefits to using apremilast for plaque psoriasis patients.

The 0.002% eye drops were designated for the reduction of elevated IOP in patients with primary open-angle glaucoma or ocular hypertension.

"Collectively, this work highlights and supports chronotype as a potential risk factor related to type 2 diabetes and cardiovascular disease risk," investigators wrote.

The phase 2 Ladder trial indicated no evidence of worse macular atrophy with PDS compared with intravitreal ranibizumab 0.5-mg injections.

SGLT2 inhibitors, ARNIs, and MRAs were associated with a significant decrease in hospital admission for heart failure.

A significantly lower rate of C difficile resolution was found in the placebo group compared to the FMT group.

A study from the Netherlands suggests steps to address patients’ sleep health.

Various consequences have been linked to nightmares and can have a severe impact on mental health, even leading to increased risk of suicide.

A study in China found that Parkinson’s patients treated with acupuncture saw reduced anxiety levels.

New evidence from a Mount Sinai study suggested that consistent lack of sleep has negative effects on immune stem cells and increases the risk of inflammatory disorders and heart disease.

Diabetes mortality rates in 2017-2018 compared with 1999-2000 were highest and unchanged in rural counties.

The analysis suggests people with T2D newly receiving SGLT2 inhibitors may have lower risk for DED in comparison to those receiving GLP-1 RAs.

RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic.

This risk also increased with age and was amplified in patients with HCV compared to patients without HCV.

Dr. Steven Pipe talks about the profound effect the novel recombinant factor VIII candidate demonstrated in patients with hemophilia A.

"We've never had any prophylactic therapy that maintains patients at this level of hemostatic protection well into the normal range for the majority of the week," Dr. Steven Pipe says.

Trifocal IOLs were linked to greater improvement in visual acuity in uncorrected near visual acuity and enhanced uncorrected intermediate visual acuity.

Study data suggest the amount of damage to the corneal nerve fibers increased in line with the amount of impairment to glucose metabolism.

A discussion on research into allergic contact dermatitis and its connection to allergens in skincare products.

DBV Technologies is expected to provide additional updates after a consultation with the FDA.